Pharma Exclusives Pressreleases
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
Friday, February 21, 2025Teva Pharmaceuticals a US affiliate of Teva Pharmaceutical Industries Ltd NYSE and TASE TEVA and Alvotech NASDAQ ALVO today announced the availability of SELARSDI ustekinumabaekn injection in the US a biosimilar to Stelara ustekinumab for the treatme...
Biogen and Stoke Therapeutics Partner to Develop and Market Zorevunersen for Dravet Syndrome Treatment
Wednesday, February 19, 2025Biogen Incand Stoke Therapeutics Inctoday announced a collaboration for the development and commercialization of zorevunersen a potential firstinclass disease modifying medicine in development for the treatment of Dravet syndrome in all territories o...
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
Wednesday, February 19, 2025Gilead Sciences Inc today announced that the US Food and Drug Administration FDA has accepted its New Drug Application NDA submissions for lenacapavirthe companys twiceyearly injectable HIV capsid inhibitorfor the prevention of HIV as preexposure pro...
WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications
Tuesday, February 18, 2025Merck known as MSD outside of the United States and Canada today announced that the European Commission EC has conditionally approved WELIREG Mercks oral hypoxiainducible factor alpha
Bio-Techne Announces Release of GMP TcBuster Non-Viral Genome Engineering System
Tuesday, February 18, 2025BioTechne Corporation a leading provider of innovative life science research tools is pleased to announce the official release of GMP Transposase mRNA for the TcBuster nonviral genome engineering system supporting the development and manufacture of i...
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
Tuesday, February 18, 2025Lexicon Pharmaceuticals Inc today announced The Lancet Diabetes Endocrinology has published a research paper analyzing the ability of sotagliflozin a dual SGLT and SGLT inhibitor to reduce the risks of lifethreatening cardiovascular outcomes
Thermo Fisher Scientific’s New Spatial Imaging System Enables Researchers to Generate High-quality Data, Making it Easier to Enter the Field of Spatial Tissue Proteomics
Thursday, February 13, 2025Thermo Fisher Scientific Inc the world leader in serving science today introduced the Invitrogen EVOS S Spatial Imaging System This advanced system addresses the limitations of current fluorescent microscopy technologies by enabling researchers to ge...
Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training
Thursday, February 13, 2025Allergan Aesthetics an AbbVie company today announced Allergan Medical Institute AMI will open three new stateoftheart training centers in the US expanding access to highquality tailored training to licensed aesthetics providers AMIs unique curriculu...
Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104
Thursday, February 13, 2025Kiora Pharmaceuticals Inc announced that the US Patent and Trademark Office has issued a compositionofmatter patent USB on a specific crystalline form or polymorph of KIO KIO is a novel nonsteroidal antiinflammatory small molecule inhibitor of dihydr...
Prenetics Announces Genomics-Based Partnership with Humanity Protocol and Launches Crypto Strategic Reserve
Wednesday, February 12, 2025Prenetics Global Limited a leading genomics and consumer healthcare company today announced a groundbreaking genomicsbased partnership with Humanity Protocol a decentralized identity verification company This collaboration leverages Prenetics advance...
